| Autor: |
Yi-Chieh Lin, Yin-Ling Tan, Ting-An Yen, Chien-Yi Chen, Po-Nien Tsao, Hung-Chieh Chou |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Pediatrics, Vol 10 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2296-2360 |
| DOI: |
10.3389/fped.2022.817624 |
| Popis: |
BackgroundMethylxanthines (caffeine; aminophylline/theophylline) are commonly used for apnea of prematurity (AOP) treatment. We aimed to compare the efficacy and adverse effects of caffeine and aminophylline/theophylline.MethodsA retrospective case–control gestational age-matched study investigates patients born between January 2017 and December 2018, 23–35 weeks gestation with birth weights >500 g treating AOP with caffeine or aminophylline/theophylline.ResultsThere were 144 cases (48 in caffeine group and 96 in aminophylline/theophylline group). The median treatment durations were 11 and 17 days in caffeine and aminophylline/theophyllinegroup (p = 0.002). When tachycardia is defined as heart rate ≥160 bpm, the rates were 8.3 and 34.4% in caffeine and control group (p = 0.001). When tachycardia is defined as 10 bpm over baseline heart rate, the rates were 41.7 and 63.5% in caffeine and aminophylline/theophylline group (p = 0.01). Stratified by gestational age and sex, significant reductions in tachycardia rates with caffeine than with theophylline were limited to male infants and infants born at |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
